Belite Bio, Inc

Informe acción NasdaqCM:BLTE

Capitalización de mercado: US$1.2b

Belite Bio Dirección

Dirección controles de criterios 1/4

El CEO de Belite Bio's es Tom Lin, nombrado en Nov 2021, tiene una permanencia de 2.42 años. posee directamente un 1.82% de las acciones de la empresa, con un valor de $20.21M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 2.4 años, respectivamente.

Información clave

Tom Lin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO2.5yrs
Participación del CEO1.8%
Permanencia media de la dirección2.5yrs
Promedio de permanencia en la Junta Directiva2.5yrs

Actualizaciones recientes de la dirección

Recent updates

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10
An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31
Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Sep 16

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Aug 22

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Aug 12

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Aug 01
Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

CEO

Tom Lin (44 yo)

2.5yrs

Permanencia

Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Yu-Hsin Lin
Chairman of the Board of Directors & CEO2.5yrssin datos1.82%
$ 22.4m
Hao-Yuan Chuang
CFO & Director4.1yrssin datos1.07%
$ 13.1m
Nathan Mata
Chief Scientific Officer2.5yrssin datossin datos

2.5yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BLTE se considera experimentado (2.4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Yu-Hsin Lin
Chairman of the Board of Directors & CEO6.2yrssin datos1.82%
$ 22.4m
Hao-Yuan Chuang
CFO & Director2.5yrssin datos1.07%
$ 13.1m
Frank Holz
Member of Ophthalmology Clinical Advisory Boardno datasin datossin datos
Yuan Lu
Independent Director2.1yrssin datossin datos
Quan Dong Nguyen
Member of Ophthalmology Clinical Advisory Boardno datasin datossin datos
Hendrik Scholl
Member of Ophthalmology Clinical Advisory Boardno datasin datossin datos
Michel Michaelides
Member of Ophthalmology Clinical Advisory Boardno datasin datossin datos
Wan-Shan Chen
Director2.5yrssin datossin datos
Hung-Wei Chen
Director2.5yrssin datossin datos
John Longo
Independent Director2.1yrssin datossin datos
Gary Biddle
Independent Director2.1yrssin datossin datos
Robyn Guymer
Member of Ophthalmology Clinical Advisory Boardno datasin datossin datos

2.5yrs

Permanencia media

44yo

Promedio de edad

Junta con experiencia: La junta directiva de BLTE no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.